Jake Orlick, an 11-year-old boy, is fighting a courageous battle against Ewing Sarcoma, a rare form of bone cancer. Our Patrick Grohar, MD, PhD, an attending physician with the Cancer Center and the Director of Translational Research with the Center of Childhood Cancer Research, may be on the verge of a breakthrough with a novel new experimental treatment for relapsed Ewing sarcoma. Here’s more in this story reported by Erin Coleman on NBC10 Philadelphia.
Grohar, at CHOP, is about to launch human testing of two already approved chemotherapies, trabectedin and irinotecan, because his lab research suggests that the combination can inhibit a crucial mutation in Ewing sarcoma. Trabectedin has also been shown to have other targeted and immune-boosting effects.
Featured in this article
Specialties & Programs
Jake Orlick, an 11-year-old boy, is fighting a courageous battle against Ewing Sarcoma, a rare form of bone cancer. Our Patrick Grohar, MD, PhD, an attending physician with the Cancer Center and the Director of Translational Research with the Center of Childhood Cancer Research, may be on the verge of a breakthrough with a novel new experimental treatment for relapsed Ewing sarcoma. Here’s more in this story reported by Erin Coleman on NBC10 Philadelphia.
Grohar, at CHOP, is about to launch human testing of two already approved chemotherapies, trabectedin and irinotecan, because his lab research suggests that the combination can inhibit a crucial mutation in Ewing sarcoma. Trabectedin has also been shown to have other targeted and immune-boosting effects.
Contact us
Cancer Center